Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Text availability
Article attribute
Article type
Publication date

Search Results

1,031 results
Filters applied: . Clear all Results are displayed in a computed author sort order. Results by year timeline is unavailable
Page 1
Response criteria for clinical trials on osteoarthritis of the knee and hip: a report of the Osteoarthritis Research Society International Standing Committee for Clinical Trials response criteria initiative.
Dougados M, Leclaire P, van der Heijde D, Bloch DA, Bellamy N, Altman RD. Dougados M, et al. Among authors: van der heijde d. Osteoarthritis Cartilage. 2000 Nov;8(6):395-403. doi: 10.1053/joca.2000.0361. Osteoarthritis Cartilage. 2000. PMID: 11069723 Review.
Minimum clinically important improvement and patient acceptable symptom state in pain and function in rheumatoid arthritis, ankylosing spondylitis, chronic back pain, hand osteoarthritis, and hip and knee osteoarthritis: Results from a prospective multinational study.
Tubach F, Ravaud P, Martin-Mola E, Awada H, Bellamy N, Bombardier C, Felson DT, Hajjaj-Hassouni N, Hochberg M, Logeart I, Matucci-Cerinic M, van de Laar M, van der Heijde D, Dougados M. Tubach F, et al. Among authors: van der heijde d, van de laar m. Arthritis Care Res (Hoboken). 2012 Nov;64(11):1699-707. doi: 10.1002/acr.21747. Arthritis Care Res (Hoboken). 2012. PMID: 22674853
Efficacy of cyclo-oxygenase-2 inhibition by etoricoxib and naproxen on the axial manifestations of ankylosing spondylitis in the presence of peripheral arthritis.
Gossec L, van der Heijde D, Melian A, Krupa DA, James MK, Cavanaugh PF, Reicin AS, Dougados M. Gossec L, et al. Among authors: van der heijde d. Ann Rheum Dis. 2005 Nov;64(11):1563-7. doi: 10.1136/ard.2004.029611. Epub 2005 Feb 24. Ann Rheum Dis. 2005. PMID: 15731291 Free PMC article. Clinical Trial.
Evaluation of clinically relevant changes in patient reported outcomes in knee and hip osteoarthritis: the minimal clinically important improvement.
Tubach F, Ravaud P, Baron G, Falissard B, Logeart I, Bellamy N, Bombardier C, Felson D, Hochberg M, van der Heijde D, Dougados M. Tubach F, et al. Among authors: van der heijde d. Ann Rheum Dis. 2005 Jan;64(1):29-33. doi: 10.1136/ard.2004.022905. Epub 2004 Jun 18. Ann Rheum Dis. 2005. PMID: 15208174 Free PMC article.
Efficacy of celecoxib, a cyclooxygenase 2-specific inhibitor, in the treatment of ankylosing spondylitis: a six-week controlled study with comparison against placebo and against a conventional nonsteroidal antiinflammatory drug.
Dougados M, Béhier JM, Jolchine I, Calin A, van der Heijde D, Olivieri I, Zeidler H, Herman H. Dougados M, et al. Among authors: van der heijde d. Arthritis Rheum. 2001 Jan;44(1):180-5. doi: 10.1002/1529-0131(200101)44:1<180::AID-ANR24>3.0.CO;2-K. Arthritis Rheum. 2001. PMID: 11212158 Clinical Trial.
Rofecoxib, a new cyclooxygenase 2 inhibitor, shows sustained efficacy, comparable with other nonsteroidal anti-inflammatory drugs: a 6-week and a 1-year trial in patients with osteoarthritis. Osteoarthritis Studies Group.
Saag K, van der Heijde D, Fisher C, Samara A, DeTora L, Bolognese J, Sperling R, Daniels B. Saag K, et al. Among authors: van der heijde d. Arch Fam Med. 2000 Nov-Dec;9(10):1124-34. doi: 10.1001/archfami.9.10.1124. Arch Fam Med. 2000. PMID: 11115219 Clinical Trial.
1,031 results